Anti-Hu CD138 FITC

Anti-Hu CD138 FITC

• Background: CD138 (syndecan 1) is a transmembrane proteoglycan that can bind a variety of cytokines and modulate their activity, as well as the activity of extracellular matrix components and influence many developmental processes. CD138 is expressed mainly in differentiating keratinocytes and is transiently upregulated in all layers of the epidermis upon tissue injury. It is also highly expressed on plasma cells and can be detected even on fibroblasts, vascular smooth muscle cells and endothelial cells. Up-regulation and down-regulation of CD138 on the cell surface often correlates with the gain of cancerous characteristics. Serum levels of the shedded soluble sCD138 are used as a prognostic factor of cancerogenesis.
• Specifications: The mouse monoclonal antibody MI15 recognizes an extracellular epitope of CD138 (syndecan 1), a 65-70 kDa heparan sulfate proteoglycan expressed mainly in the epidermis and plasma cells, but also in growth factor-stimulated lymphocytes.
• Certification: RUO
• Host: Mouse
• Species Reactivity: Human, Non-human primates
• Immunogen: A mixture of U266 and XG-1 human myeloma cell lines
• Target Antigen: CD138
• Isotype: Igg1 κ
• Clone: MI15
• Applications: Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 mL) is sufficient for 100 tests.
• Validated Applications: FC
• Format: FITC
• Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
• References & Citations: *Nadalin MR, Fregnani ER, Silva-Sousa YT, Perez DE: Syndecan-1 (CD138) and Ki-67 expression in odontogenic cystic lesions. Braz Dent J. 201122(3):223-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/21915520,*Jourdan M, Caraux A, Caron G, Robert N, Fiol G, Rème T, Bolloré K, Vendrell JP, Le Gallou S, Mourcin F, De Vos J, Kassambara A, Duperray C, Hose D, Fest T, Tarte K, Klein B: Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation. J Immunol. 2011 Oct 15187(8):3931-41., URL: https://www.ncbi.nlm.nih.gov/pubmed/21918187,*Noll JE, Vandyke K, Hewett DR, Mrozik KM, Bala RJ, Williams SA, Kok CH, Zannettino AC: PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol. 2015 Oct 68:106., URL: https://pubmed.ncbi.nlm.nih.gov/26445238/,*Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N: Role of interleukin 16 in multiple myeloma. J Natl Cancer Inst. 2012 Jul 3104(13):1005-20., URL: https://www.ncbi.nlm.nih.gov/pubmed/22745469,*Krishnan SR, Luk F, Brown RD, Suen H, Kwan Y, Bebawy M: Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma. Neoplasia. 2016 Jan18(1):25-32., URL: https://pubmed.ncbi.nlm.nih.gov/26806349/,*Gattei V, Godeas C, Degan M, Rossi FM, Aldinucci D, Pinto A: Characterization of anti-CD138 monoclonal antibodies as tools for investigating the molecular polymorphism of syndecan-1 in human lymphoma cells. Br J Haematol. 1999 Jan104(1):152-62., URL: https://www.ncbi.nlm.nih.gov/pubmed/10027728,*Quardokus EM, Saunders DC, McDonough E, Hickey JW, Werlein C, Surrette C, Rajbhandari P, Martinez Casals A, Tian H, Lowery L, Neumann EK, Björklund F, Neelakantan TV, Croteau J, Wiblin AE, Fisher J, Livengood AJ, Dowell KG, Silverstein JC, Spraggins JM, Pryhuber GS, Deutsch G, Ginty F, Nolan GP, Melov S, Jonigk D, Caldwell MA, Vlachos IS, Mueller W, Gehlenborg N, Stockwell BR, Lundberg E, Snyder MP, Germain RN, Camarillo JM, Kelleher NL, Börner K, Radtke AJ: Organ mapping antibody panels: a community resource for standardized multiplexed tissue imaging. Nat Methods 2023 Aug20(8):1174-1178. doi: 10.1038/s41592-023-01846-7., URL: https://pubmed.ncbi.nlm.nih.gov/37468619/,
• Other References: *Hayashida K, Johnston DR, Goldberger O, Park PW: Syndecan-1 expression in epithelial cells is induced by transforming growth factor beta through a PKA-dependent pathway. J Biol Chem. 2006 Aug 25281(34):24365-74., URL: https://www.ncbi.nlm.nih.gov/pubmed/16807246?ordin,*Choi DS, Kim JH, Ryu HS, Kim HC, Han JH, Lee JS, Min CK: Syndecan-1, a key regulator of cell viability in endometrial cancer. Int J Cancer. 2007 Aug 15121(4):741-50., URL: https://www.ncbi.nlm.nih.gov/pubmed/17455248?ordin,*Manakil JF, Seymour GJ, Bartold PM: Effect of cytokine and antigen stimulation on peripheral blood lymphocyte syndecan-1 expression. Oral Microbiol Immunol. 2007 Aug22(4):272-6., URL: https://www.ncbi.nlm.nih.gov/pubmed/17600540?ordin,*Muto T, Miyoshi K, Munesue S, Nakada H, Okayama M, Matsuo T, Noma T: Differential expression of syndecan isoforms during mouse incisor amelogenesis. J Med Invest. 2007 Aug54(3-4):331-9., URL: https://www.ncbi.nlm.nih.gov/pubmed/17878683?ordin,*Ojeh N, Hiilesvuo K, Wärri A, Salmivirta M, Henttinen T, Määttä A: Ectopic expression of syndecan-1 in basal epidermis affects keratinocyte proliferation and wound re-epithelialization. J Invest Dermatol. 2008 Jan128(1):26-34., URL: http://www.ncbi.nlm.nih.gov/pubmed/17625591?ordina,*Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O'Brien SM, Giles FJ, Albitar M: Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2008 Jan 7., URL: http://www.ncbi.nlm.nih.gov/pubmed/18190591?ordina,
• Storage Conditions: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.